Glaukos CORP

Glaukos Corporation presented an investor presentation highlighting its innovative pipeline, strong financial health, and strategic focus on interventional glaucoma and keratoconus treatments.

Glaukos Corporation announced record second quarter 2026 financial results, with net sales soaring 50% year-over-year to $185.6 million, prompting an increase in full-year revenue guidance.

Glaukos Corporation's annual meeting saw stockholders vote on director elections, executive compensation, and auditor ratification, with all proposals passing.

Glaukos Corporation presented its latest investor materials in May 2026, detailing advancements in its interventional glaucoma and keratoconus therapies, alongside a robust product pipeline and positive financial outlook.

Glaukos Corporation presents its investor update, showcasing significant growth, a robust product pipeline, and strategic initiatives in interventional glaucoma and keratoconus.

Glaukos Corporation announced preliminary, unaudited net sales for Q4 and full year 2025, showing significant growth, and reaffirmed its 2026 revenue guidance.

Glaukos Corporation reported a significant 50% increase in net sales for the second quarter of 2026, reaching $185.6 million, primarily fueled by strong performance of its iDose TR product.

Glaukos Corporation reported a 38% increase in net sales for Q3 2025, driven by strong iDose TR performance and the recent FDA approval of Epioxa, despite ongoing reimbursement challenges and a net loss.

Glaukos Corporation reported a significant reduction in net loss for the second quarter and first half of 2025, driven by robust sales growth in glaucoma products, particularly iDose TR, and improved gross margins.

Glaukos Corp's Q1 2025 revenue increased by 25% year-over-year, driven by iDose TR sales, but the company still reported a net loss.

Glaukos Corporation's Q3 2024 results show a 24% increase in revenue compared to the same period last year, driven by growth in glaucoma and corneal health product sales.

Glaukos Corporation's Q2 2024 results show a 19% increase in net sales, driven by glaucoma product growth and the launch of iDose TR, despite a net loss of $50.5 million.

Glaukos Corporation's 2024 10-K filing reveals a year of significant growth, highlighted by the commercial launch of iDose TR and expansion in both U.S. and international markets.

Glaukos Corporation's 10-K filing highlights the FDA approval of iDose TR, its financial performance, and strategic initiatives for growth in glaucoma, corneal, and retinal treatments.

Gilbert H Kliman, a Director of GLAUKOS Corp, sold 2,500 shares of common stock on August 19, 2026 for $190.00 per share.

Joseph E Gilliam, PRESIDENT & COO of GLAUKOS Corp, sold 60,000 shares of common stock on August 11, 2026.

Alex R. Thurman, SVP & CHIEF FINANCIAL OFFICER of GLAUKOS Corp, sold 20,000 shares of common stock on August 7, 2026 for $180.13 per share.

Leana Wen, a Director of GLAUKOS Corp, sold 525 shares of common stock on July 31, 2026 for $167.63 per share.

Alex R. Thurman, SVP & CHIEF FINANCIAL OFFICER of GLAUKOS Corp, sold 10,000 shares of common stock on July 16, 2026 for $160.00 per share.

Alex R. Thurman, SVP & CHIEF FINANCIAL OFFICER of GLAUKOS Corp, sold 10,000 shares of common stock on July 9, 2026 for $155.00 per share.

Glaukos Corporation announced its 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026, and outlined key proposals including director elections and executive compensation.

Glauskos Corporation files a definitive proxy statement with the SEC.

Glaukos Corporation is soliciting proxies for its 2025 Annual Meeting of Stockholders, focusing on director elections, executive compensation approval, and auditor ratification.

Glaukos Corporation is soliciting proxies for its 2024 Annual Meeting of Stockholders, featuring proposals for director elections, an amended incentive compensation plan, and executive compensation advisory votes.

Glaukos Corporation's upcoming annual meeting on May 30, 2024, will include votes on director elections, executive compensation, and ratification of the company's independent auditor.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 5,348,395 shares of Glaukos Corp. common stock, representing 9.2% of the class.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.07% beneficial ownership stake in Glaukos Corp.

Vanguard Portfolio Management has reported a beneficial ownership of 5.6% in Glaukos Corp's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Glaukos Corp, reporting 0% beneficial ownership following an internal realignment where subsidiaries will now report separately.

Janus Henderson Group plc has reported a 5.3% beneficial ownership stake in Glaukos Corp, holding over 3 million shares.

PRIMECAP Management Co./CA/ has reported a 5.88% beneficial ownership stake in Glaukos Corporation, holding 3,376,928 shares as an investment adviser.